Nivolumab plus hyaluronidase-nvhy is approved for subcutaneous injection across all solid tumor indications previously approved for nivolumab. The CheckMate-67T trial showed subcutaneous nivolumab's ...

"As a result of the changes and the programmed phase-in of the changes, the cystoscopy code total RVU for the office setting will be 8% lower in 2025 than the current value," write Jonathan Rubenstein ...

"We're asking the bladder to come have a seat and to give voice to surgical choice," says Wayne Kuang, MD. In this video, Wayne Kuang, MD, discusses how his management of patients with benign ...

"There's a number of emerging modalities in the primary focal ablation space that are in trial at this time," says Kara L. Watts, MD. In this video, Kara L. Watts, MD, shares her predictions for ...

Studies reveal a connection between benign prostatic hyperplasia and erectile dysfunction, emphasizing the need for comprehensive patient management. Aquablation therapy receives a Category I CPT code ...

Panelists discuss how the management of metastatic castration-resistant prostate cancer with a homologous recombination repair (HRR) alteration involves targeted therapies, such as PARP inhibitors, to ...

Alkaline water may not effectively prevent kidney stones due to negligible impact on urinary pH and citrate levels. FDA cleared the RenaFlex ureteroscope system and Stone Clear device, enhancing ...

BCG-unresponsive NMIBC is defined by persistent or recurrent high-grade tumors or carcinoma in situ after adequate BCG therapy. This condition requires alternative therapeutic strategies or radical ...

The 2023 CUA guideline highlights the significance of specimen collection and timing in prostate cancer genetic testing. Practical strategies are provided to optimize genetic testing outcomes, ...

In this video, Shreyas S. Joshi, MD, MPH, highlights the background for the ongoing phase 2 LEGEND trial (NCT04752722) of detalimogene voraplasmid (EG-70) for patients with high-risk ...

A panelist discusses how identifying intermediate-risk patients, managing disease heterogeneity in non–muscle-invasive bladder cancer, and addressing long-term care needs present key challenges in ...

The ASPIRE trial showed SURE's noninferiority to URS in stone-free rate for nephrolithiasis treatment. SURE demonstrated superior stone clearance and residual stone volume outcomes, unaffected by ...